Quarterly report pursuant to Section 13 or 15(d)

Debt and Interest (Tables)

v3.10.0.1
Debt and Interest (Tables)
 9 Months Ended
Sep. 30, 2018
Debt Disclosure [Abstract]  
Schedule Of Interest Expenses
Total debt consists of the following as of September 30, 2018 and December 31, 2017:
 
($ in thousands)
 
September 30,
2018
 
 
December 31,
2017
 
 
Interest Rate
 
 
Maturity
IDB Note
 
$
14,929
 
 
$
14,929
 
 
 
2.25
%
 
August - 2020
2017 Subordinated Note Financing
 
 
3,254
 
 
 
3,254
 
 
 
8.00
%
 
March - 2020
2017 Subordinated Note Financing
 
 
13,893
 
 
 
13,893
 
 
 
8.00
%
 
May - 2020
2017 Subordinated Note Financing
 
 
1,820
 
 
 
1,820
 
 
 
8.00
%
 
June - 2020
2017 Subordinated Note Financing
 
 
3,018
 
 
 
3,018
 
 
 
8.00
%
 
August - 2020
2017 Subordinated Note Financing
 
 
6,371
 
 
 
6,371
 
 
 
8.00
%
 
September - 2020
2018 Venture Notes
 
 
6,517
 
 
 
-
 
 
 
8.00
%
 
February - 2021
2018 Venture Notes
 
 
15,190
 
 
 
-
 
 
 
8.00
%
 
March - 2021
Opus Credit
Facility
1
 
 
9,500
 
 
 
9,500
 
 
 
12.00
%
 
September - 2019
Helocyte Convertible Note, at fair value
2
 
 
-
 
 
 
1,000
 
 
 
8.00
%
 
December - 2017
Helocyte Convertible Note, at fair value
1, 2
 
 
300
 
 
 
2,194
 
 
 
8.00
%
 
September - 2018
Helocyte Convertible Note, at fair value2
 
 
-
 
 
 
1,062
 
 
 
8.00
%
 
April - 2018
Helocyte Convertible Note, at fair value
1,2
 
 
23
 
 
 
444
 
 
 
8.00
%
 
November - 2018
Helocyte Convertible Note, at fair value
1
 
 
10
 
 
 
-
 
 
 
8.00
%
 
October - 2018
Caelum Convertible Note, at fair value
1
 
 
1,044
 
 
 
1,017
 
 
 
8.00
%
 
January - 2019
Caelum Convertible Note, at fair value
1
 
 
7,082
 
 
 
6,900
 
 
 
8.00
%
 
February - 2019
Caelum Convertible Note, at fair value
1
 
 
2,198
 
 
 
2,142
 
 
 
8.00
%
 
March - 2019
Total notes payable
 
 
85,149
 
 
 
67,544
 
 
 
 
 
 
 
Less: Discount on notes payable
 
 
892
 
 
 
1,035
 
 
 
 
 
 
 
Total notes payable
 
$
84,257
 
 
$
66,509
 
 
 
 
 
 
 
 
 
(1)
Classified as short-term on the Company’s Condensed Consolidated Balance Sheet as of September 30, 2018.
 
(2)
Classified as short-term on the Company’s Condensed Consolidated Balance Sheet as of December 31, 2017.
Schedule Of Interest Expenses For Debt Arrangements
The following table shows the details of interest expense for all debt arrangements during the periods presented. Interest expense includes contractual interest and amortization of the debt discount and amortization of fees represents fees associated with loan transaction costs, amortized over the life of the loan: 
 
 
 
Three Months Ended September 30,
 
 
Nine Months Ended September 30,
 
($ in thousands)
 
2018
 
 
2017
 
 
2018
 
 
2017
 
IDB Note
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Interest
 
$
85
 
 
$
85
 
 
$
254
 
 
$
254
 
Total IDB Note
 
 
85
 
 
 
85
 
 
 
254
 
 
 
254
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NSC Debt
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Interest
 
 
-
 
 
 
(8
)
 
 
-
 
 
 
147
 
Amortization of fees
 
 
-
 
 
 
127
 
 
 
-
 
 
 
200
 
Total NSC Debt
 
 
-
 
 
 
119
 
 
 
-
 
 
 
347
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2017 Subordinated Note Financing
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Interest
 
 
1,060
 
 
 
755
 
 
 
3,157
 
 
 
1,161
 
Amortization of fees
 
 
28
 
 
 
208
 
 
 
79
 
 
 
383
 
Total 2017 Subordinated Note Financing
 
 
1,088
 
 
 
963
 
 
 
3,236
 
 
 
1,544
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Opus Credit Facility
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Interest
 
 
288
 
 
 
287
 
 
 
853
 
 
 
798
 
Amortization of fees
 
 
105
 
 
 
282
 
 
 
525
 
 
 
733
 
Total Opus Note
 
 
393
 
 
 
569
 
 
 
1,378
 
 
 
1,531
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2018 Venture Notes
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Interest
 
 
438
 
 
 
-
 
 
 
923
 
 
 
-
 
Amortization of fees
 
 
10
 
 
 
-
 
 
 
20
 
 
 
-
 
Total 2018 Venture Notes
 
 
448
 
 
 
-
 
 
 
943
 
 
 
-
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LOC Fees
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Interest
 
 
7
 
 
 
7
 
 
 
23
 
 
 
22
 
Total LOC
 
 
7
 
 
 
7
 
 
 
23
 
 
 
22
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Helocyte Convertible Note
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Interest
 
 
6
 
 
 
64
 
 
 
93
 
 
 
175
 
Financing fee
 
 
-
 
 
 
-
 
 
 
-
 
 
 
1
 
Total Helocyte Convertible Note
 
 
6
 
 
 
64
 
 
 
93
 
 
 
176
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Avenue Convertible Note
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Interest
 
 
-
 
 
 
-
 
 
 
-
 
 
 
5
 
Financing fee
 
 
-
 
 
 
-
 
 
 
-
 
 
 
3
 
Total Avenue Convertible Note
 
 
-
 
 
 
-
 
 
 
-
 
 
 
8
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Caelum Convertible Note
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Interest
 
 
198
 
 
 
68
 
 
 
589
 
 
 
68
 
Financing fee
 
 
-
 
 
 
1,317
 
 
 
-
 
 
 
1,317
 
Total Caelum Convertible Note
 
 
198
 
 
 
1,385
 
 
 
589
 
 
 
1,385
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Falk CSR
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Interest
 
 
-
 
 
 
26
 
 
 
(64
)
 
 
26
 
Total Falk CSR
 
 
-
 
 
 
26
 
 
 
(64
)
 
 
26
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Other
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Interest
 
 
3
 
 
 
2
 
 
 
3
 
 
 
5
 
Total D&O Insurance
 
 
3
 
 
 
2
 
 
 
3
 
 
 
5
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total Interest Expense and Financing Fee
 
$
2,228
 
 
$
3,220
 
 
$
6,455
 
 
$
5,298